The abstract is read at the publisher; the summary is JClub's.
Proteogenomic profiling of 112 pediatric and AYA high-grade glioma patients (ages 0–40) reveals two age-defined AYA subgroups with distinct molecular profiles and survival outcomes.
- Why it matters: Age-related neurodevelopmental variation can confound tumor-intrinsic biology, and clinicians need molecular targets that reflect true disease differences across childhood to AYA.
- What they did: The study performed comprehensive proteogenomic analyses across tumors from 112 patients, using tumor–normal comparisons and survival modeling, plus causal network analysis and cell line studies to nominate kinase targets such as CDK8.
- The result: Oxidative phosphorylation and neuronal system biology are linked to glioma progression, and proteins, post-translational modifications, and immune signatures are associated with outcomes, including clinically relevant male–female differences.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.